Larotrectinib‐related adverse events that resulted in dose reductions were unusual in this study; in a study of 55 patients with TRK fusion‐positive cancer, therapy was not halted for any of the patients due to drug‐related unwanted effects.42 The gene discussed is NTRK1; the disease is cancer.